CareDx, Inc (CDNA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CareDx, Inc (CDNA) Healthcare & Pipeline Overview

CareDx, Inc. pioneers diagnostic solutions for transplant patients, offering AlloSure and AlloMap to monitor organ health post-transplant. With a focus on precision medicine and a growing suite of NGS-based HLA typing solutions, CareDx addresses the critical needs of the transplant community, operating within the expanding medical diagnostics sector.

What Is the Investment Thesis for CDNA?

CareDx presents a notable research candidate within the transplant diagnostics market. The company's revenue is driven by its innovative AlloSure and AlloMap testing services, which address a critical need for non-invasive monitoring of transplant rejection. With a gross margin of 68.6%, CareDx demonstrates strong profitability potential as it scales its operations. Growth catalysts include the expansion of AlloSure and AlloMap into new transplant types and geographies, as well as the increasing adoption of NGS-based HLA typing solutions. Key risks include competition from other diagnostic companies and potential changes in reimbursement policies. Investors should monitor the company's ability to maintain its market share and expand its product portfolio to sustain long-term growth.

Based on FMP financials and quantitative analysis

CDNA Key Highlights

Market Cap of $2.41B reflects investor confidence in CareDx's growth potential within the transplant diagnostics market.

• Gross Margin of 68.6% indicates strong pricing power and efficient cost management in the delivery of diagnostic services.
• Profit Margin of -2.0% suggests ongoing investments in R&D and commercial expansion, with potential for future profitability improvements.
• Beta of 2.54 indicates higher volatility compared to the market, reflecting the growth-oriented nature of the company.
• Focus on non-invasive diagnostic solutions positions CareDx to capitalize on the increasing demand for patient-friendly monitoring technologies in transplant care.

Who Are CDNA's Competitors?

CDNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDNA's Key Strengths?

Proprietary diagnostic technologies for transplant monitoring.

• Established market position in transplant diagnostics.
• Strong relationships with transplant centers and physicians.
• Comprehensive suite of solutions for transplant patients.

What Are CDNA's Weaknesses?

Limited geographic reach compared to larger diagnostic companies.

• Dependence on reimbursement policies for diagnostic testing.
• Negative profit margin.
• High beta value indicates higher volatility.

What Could Drive CDNA Stock Higher?

Expansion of AlloSure and AlloMap into new transplant types (e.g., intestinal, multi-organ) by 2028.

• Increasing adoption of NGS-based HLA typing solutions, driving revenue growth.
• Strategic partnerships and acquisitions to expand product portfolio and market reach.
• Potential positive changes in reimbursement policies for diagnostic testing.

What Are the Key Risks for CDNA?

Negative return on equity (-2.4%) — the business is not currently generating profit on shareholder capital.

• Competition from other diagnostic companies offering similar testing services.
• Changes in reimbursement policies for diagnostic testing, affecting revenue.
• Patent expiration risks for key diagnostic technologies.
• Economic downturn affecting healthcare spending and demand for diagnostic testing.
• Regulatory hurdles and compliance requirements for diagnostic products.

What Are the Growth Opportunities for CDNA?

• Expansion of AlloSure and AlloMap into New Transplant Types: CareDx has the opportunity to expand the use of its AlloSure and AlloMap testing services into new transplant types, such as intestinal and multi-organ transplants. This expansion would significantly increase the addressable market for these products. The market size for transplant diagnostics is projected to reach $10 billion by 2030, providing a substantial growth opportunity for CareDx. Timeline: 2026-2028.
• Increased Adoption of NGS-Based HLA Typing Solutions: CareDx's TruSight HLA and AlloSeq Tx solutions offer high-resolution HLA typing, which is essential for accurate donor-recipient matching. The increasing adoption of NGS technology in HLA typing presents a significant growth opportunity for CareDx. The global HLA typing market is estimated at $500 million annually. Timeline: Ongoing.
• Geographic Expansion into International Markets: CareDx has the opportunity to expand its geographic reach into international markets, such as Europe and Asia. These markets offer significant growth potential for the company's diagnostic solutions. The international transplant diagnostics market is estimated to be worth $2 billion. Timeline: 2027-2029.
• Development of New Diagnostic Solutions for Transplant Patients: CareDx can leverage its expertise in transplant diagnostics to develop new solutions for monitoring and managing transplant patients. This includes developing new tests for detecting infections and other complications. The market for new transplant diagnostic solutions is estimated at $1 billion. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: CareDx can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This includes partnering with other diagnostic companies and acquiring companies with complementary technologies. The market for transplant-related acquisitions is estimated at $500 million. Timeline: Ongoing.

What Are CDNA's Competitive Advantages?

• Proprietary diagnostic technologies, such as AlloSure and AlloMap.
• Established relationships with transplant centers and physicians.
• Extensive database of transplant patient data.
• Strategic partnerships with leading companies in the transplant field.

What Does CDNA Do?

CareDx, Inc., founded in 1998 and formerly known as XDx, Inc., is a precision medicine company dedicated to improving the lives of transplant patients. Headquartered in South San Francisco, California, CareDx discovers, develops, and commercializes diagnostic solutions that address the critical needs of transplant recipients and their caregivers. The company's flagship products include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are donor-derived cell-free DNA (dd-cfDNA) and gene expression solutions used to monitor the health of transplanted organs. These non-invasive tests provide clinicians with valuable insights into organ rejection, enabling timely intervention and improved patient outcomes. CareDx also offers a range of HLA typing solutions, including TruSight HLA, Olerup SSP, and QTYPE, which are used to determine the compatibility between donors and recipients. These solutions are based on next-generation sequencing (NGS) and sequence-specific primer technology, providing high-resolution typing for accurate matching. Additionally, CareDx provides Ottr, a transplant patient management software, and AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company markets its products directly to customers and through third-party distributors and sub-distributors. CareDx has strategic partnerships with companies like Illumina, Inc. and Cibiltech SAS to expand its product offerings and market reach.

What Products and Services Does CDNA Offer?

• Develops and commercializes diagnostic solutions for transplant patients.
• Offers AlloSure Kidney, a dd-cfDNA solution for kidney transplant patients.
• Provides AlloMap Heart, a gene expression solution for heart transplant patients.
• Offers AlloSure Heart and AlloSure Lung, dd-cfDNA solutions for heart and lung transplant patients.
• Provides TruSight HLA, an NGS-based high-resolution typing solution.
• Offers Ottr, a transplant patient management software.
• Provides AlloSeq Tx, a high-resolution HLA typing solution.

How Does CDNA Make Money?

• Direct sales of diagnostic solutions to hospitals and transplant centers.
• Sales through third-party distributors and sub-distributors.
• Revenue from testing services, such as AlloSure and AlloMap.
• Licensing agreements for the distribution, development, and commercialization of NGS products and technologies.

What Industry Does CDNA Operate In?

CareDx operates within the medical diagnostics industry, specifically focusing on transplant diagnostics. The industry is characterized by increasing demand for non-invasive monitoring solutions and personalized medicine approaches. The market for transplant diagnostics is driven by the growing number of transplant procedures performed globally and the need for improved patient outcomes. CareDx competes with other diagnostic companies offering similar testing services, as well as larger players in the HLA typing market. The company's focus on innovation and strategic partnerships positions it to capitalize on the growth opportunities within the industry.

Who Are CDNA's Key Customers?

• Transplant centers and hospitals.
• Transplant physicians and surgeons.
• Histocompatibility laboratories.
• Transplant patients and caregivers.

Company Profile

CareDx, Inc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Brisbane, US. The company is led by CEO John Walter Hanna Jr.. CDNA has traded publicly since 2014.

Return on equity for CareDx, Inc stands at -2.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. CDNA trades at a trailing price-to-earnings ratio of 23.92, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

CDNA Valuation & Market Position

With a $2.41B market cap, CareDx, Inc sits in the mid-cap segment of the market. Relative to its peer group, CDNA's quantitative score of 96/100 is above the peer average of 67/100.

Quarterly Financial Performance: CareDx, Inc

Revenue for CareDx, Inc came in at $131.9M during Q2 2026, a 12.1% improvement versus the preceding quarter. The company recorded net income of $110.6M, with diluted EPS of $2.07. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, CDNA averaged $0.52 in diluted EPS.

CareDx, Inc's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 13.70 places it in the safe zone, indicating low near-term bankruptcy risk.

CareDx, Inc has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 310.0% above estimates on average.

Wall Street analysts project CareDx, Inc revenue of about $472.8M for fiscal 2026, with EPS near $1.05. The estimate reflects 5 contributing analysts.

CDNA Financials

CDNA Latest News

CDNA Analyst Consensus

CDNA MoonshotScore

Latest CareDx, Inc Analysis

CDNA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources